← Eichor
Study identifier: NCT06463938 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH

Condition: Dentin Sensitivity · Hypersensitivity · Cervical Lesion  ·  Sponsor: Dow University of Health Sciences

PhaseNA
Planned participants120
Who can joinAll sexes, 25 Years to 65 Years
Healthy volunteersYes

About this study

Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).

This description comes directly from the study's public registry record.

Talk to the study team

Sanam Dr Faheem, MSc  ·  021-38771000  ·  sanam.faheem@duhs.edu.pk

Chandar Dr Kumar  ·  021-38771000  ·  chander.kumar@duhs.edu.pk

Always discuss trial participation with your own doctor first.

Locations (1)

Dr Sanam FaheemKarachi, Sindh, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06463938